High expression level of ERBB2 and efficacy of trastuzumab deruxtecan in desmoplastic small round cell tumour: a monocentric case series report
This case series presents a major information, suggesting that HER2 is a therapeutic target in DSRCT and T-DXd might represent a novel therapeutic option. Those results require to be rapidly shared with the scientific community and confirmed in a prospective clinical trial in this context of very poor prognosis disease and urgent unmet need.
Authors
- Hélène Vanacker
- A. Dufresne
- A. Meurgey
- V. Isnardi (ORCID: https://orcid.org/0000-0001-9264-2462)
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Margaux Dupont (ORCID: https://orcid.org/0009-0002-0959-1460)
- P. Meeus
- Franck Tirode (ORCID: https://orcid.org/0000-0003-4731-7817)
- Mehdi Brahmi (ORCID: https://orcid.org/0000-0001-9904-166X)
- Marie Karanian (ORCID: https://orcid.org/0000-0003-0434-636X)
- M.-P. Sunyach
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre de physique des particules de Marseille (FR)
- Centre Léon Bérard (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104133
- Citations
- 5
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.59